Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes is a dataset published in New England Journal of Medicine (2017). On theSindex it has a DataRank of 9.9, placing it in the top 1.3% of the data-sharing corpus. It has been cited 7,805 times, with 100 citing works in its 1-hop citation network. Its calibrated FAIR score is 84/100.
Ranks in the top 1% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Full FAIR picture · advisory
This score predates the current agent — it came from the earlier rubric, which blended repository metadata into the number and asked the model for a rating rather than an evidenced verdict. Re-evaluate the paper to score it against the current standards-anchored criteria, where every verdict is backed by a quote from the full text.
DOI present
datacite=25, pmcid=False, pmid=True
OpenAlex id present
files/OA location present but not flagged OA
20 OA location(s)
linked_datasets=25, datacite=25
accessions=1, trials=0
open license (cc-by-nc-nd)
downloads=0
no version chain
is_dataset
Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →
Base Score Contribution
1.3
From this paper's citation signal
Citation Network Contribution
8.6
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
FWCI
476.16
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ
Additional file 1 of Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ
Additional file 2 of Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Additional file 2 of Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Additional file 1 of Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Additional file 1 of Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Additional file 1 of Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
Additional file 1 of Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
Additional file 2 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
Additional file 2 of Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
Additional file 1 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Additional file 1 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Additional file 2 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Additional file 2 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Additional file 1 of The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT)
Additional file 1 of The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT)
Additional file 1 of Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
Additional file 1 of Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
Additional file 1 of Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
Additional file 1 of Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study